OncoMatch/Clinical Trials/NCT06644443
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Is NCT06644443 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies BCMA-GPRC5D CAR-T cells for multiple myeloma in relapse.
Treatment: BCMA-GPRC5D CAR-T cells — At present, MM is still an incurable disease in general, and the vast majority of patients will eventually face disease recurrence or progression. Although CAR-T therapy targeting BCMA has shown advantages in the efficacy and safety of MM, for MM patients with BCMA negative or BCMA low expression, they still relapse after receiving targeted BCMA CAR T-cell therapy, and there is a problem of target escape. The specific high expression of GPRC5D in multiple myeloma cells makes it possible to combine BCMA and GPRC5D in the treatment of MM. This study aims to investigate the safety and efficacy of BCMA-GPRC5D CAR-T therapy in the treatment of relapsed or refractory MM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) overexpression (positive)
myeloma cells have positive BCMA ... expression
Required: GPRC5D overexpression (positive)
myeloma cells have positive ... GPRC5D expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy regimen containing bortezomib (bortezomib)
use chemotherapy regimens containing bortezomib, the treatment is ineffective, or the disease progresses within 60 days after the end of the last chemotherapy
Must have received: chemotherapy regimen containing lenalidomide (lenalidomide)
use chemotherapy regimens containing lenalidomide, the treatment is ineffective, or the disease progresses within 60 days after the end of the last chemotherapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
After allogeneic hematopoietic stem cell transplantation
Lab requirements
Blood counts
hemoglobin ≥ 80g/l; ANC ≥ 1000 / mm3 (without GCSF or other growth factors); platelet count ≥ 30,000 / mm3 (no blood transfusion required)
Kidney function
blood creatinine < 2.0 mg/dl
Liver function
serum total bilirubin < 1.5 mg/dl; serum ALT or AST ≤ 2.5 x ULN
Cardiac function
NYHA cardiac function class I-II; LVEF ≥ 50%
serum total bilirubin ≥ 1.5 mg/dl; serum ALT or AST greater than 2.5 times the upper limit of normal; blood creatinine ≥ 2.0 mg/dl; hemoglobin<80g/l; does not rely on GCSF or other growth factors, the absolute neutrophil count is less than 1000 / mm3; no blood transfusion is required, and the platelet count is less than 30,000 / mm3; NYHA cardiac function classification standards, patients with grade III or IV cardiac insufficiency; or echocardiographic examination of left ventricular ejection fraction (LVEF) <50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify